October 11, 2021
Pace Life Sciences Acquires Velesco Pharmaceutical Services, Expanding Capabilities in Drug Development Services. Read the Press Release!
May 5, 2021
Newly Acquired DEA Analytical Laboratory License. We are licensed to use schedules 2, 2N, 3, 3N, 4, and 5.
February 4, 2020
New Velesco Pharma clinical manufacturing facility begins operations. Read the Press Release!
November 11, 2019
Dave Barnes, Velesco's Chief Scientist, will be giving a presentation titled "Investigational New Drug Process" at the forthcoming MichBIO Drug Development Workshop being held on Monday 11 November in Ann Arbor MI. The talk will detail the safety studies and CMC activities required for an initial IND filing.
For more information on the workshop please visit the website: MichBio Website
September 4, 2019
Velesco Pharma set for clinical manufacturing capacity expansion. Read the Press Release!
February 8, 2019
Velesco Pharma finds room to grow with Bank of Ann Arbor Technology Industry Group. Read the Press Release!
February 1, 2019
Pharmaceutical Technology spoke with Lisa Crandall, MS, associate director CMC Project Management, and Peter Angus, PhD, director of Pharmaceutical Sciences, at Velesco Pharma, which provides a full range of stability testing of API and drug products, about best practices in stability testing. Read more about the interview Determining Drug Stability.
October 23, 2018
Velesco Pharma, the expert in pharmaceutical development and clinical manufacturing, has expanded and enhanced its formulation and analytical research and development capabilities with the acquisition of a new facility in Wixom, Mich. Read the press release!
March 20, 2018
CEO Dave Barnes has been published in a Pharmaceutical Outsourcing article on Clinical Trial Materials and Manufacturing! Read the article here.
November 8, 2017
Velesco Pharmaceutical Services, Inc., has announced the award of a subcontract for analytical method development, manufacturing clinical supplies, and testing the stability of an investigational drug for the treatment for Beta-Thalassemia, a blood disorder that reduces the production of proteins that carry oxygen to cells throughout the body.
The subcontract award of $350,000 is fully funded by the National Institutes of Health's National Center for Advancing Translational Sciences (NCATS) through its Therapeutics for Rare and Neglected Diseases (TRND) program. The funds were awarded under a subcontract from Leidos Biomedical Research, Inc., prime contractor for the Frederick National Laboratory for Cancer Research. TRND staff select qualified contract research organizations to provide services supporting certain TRND drug development projects. The goal is to accelerate translation of promising therapeutics for treating rare and neglected diseases.
Beta-Thalassemia continues to be a major public health problem in many parts of the world. Through TRND, NCATS seeks to rapidly advance this potential new treatment option to the clinic.
August 2, 2016
Velesco expands its capabilities for clinical supply management by opening a new laboratory in its Plymouth, Michigan facility. The laboratory will be largely utilized for the clinical trial material storage, dispensing, inventory management and distribution of non-GMP materials such as active pharmaceutical ingredient (API), intermediates and compounds transitioning into drug development. Read more about Velesco's new materials handling laboratory.
April 1, 2016
Velesco explains how their hand-filled soft gel capsules provide cost savings during early phase drug development in a Drug Development & Delivery article! Read more about how Velesco's softgel capsules overcome the challenges with highly lipophilic compounds.
February 9, 2016
Velesco expands its cGMP compliant testing laboratory in Plymouth, Michigan with stability testing capabilities that exceed FDA compliance requirements.
Read more about Velesco's expanded testing capabilities.
January 1, 2016
Velesco's work on a chemical potency and degradation study with respect to active pharmaceutical ingredient (API) has been published in The AAPS Journal! Read about the chemical potency and degradation study.
October 15, 2015
Gerry Cox has written a guest blog post highlighting the MassBio CRO/CMO Community, specifically discussing an upcoming educational forum through MassBio.
July 17, 2015
Dave Barnes has been asked to speak at the MichBio event: Cutting Edge/Drug Discovery & Development in Michigan in Lansing on September 9-10! Dave will be featured on Panel B: Moving Beyond the Bench - Pre-Clinical Selection. View the agenda here.
May 12, 2015
Gerry Cox has recently begun serving as a co-chair of the MassBio sponsored Massachusetts CRO/CMO working group. This group organizes educational forums on industry outsourcing practices and processes that are a major force in reducing the costs and development timelines for new therapeutics.
January 30, 2014
Pharmoutsourcing has a drug formulation development roundtable discussing pharma outsourcing and features Velesco Pharmaceutical Services' CEO Dave Barnes.
August 12, 2013
Velesco's opens a new business development office in Boston in the Quincy Center for Innovation, thus expanding their drug formulation, analytical development and cGMP clinical trial manufacturing services! Read more about Velesco's new Boston office.
March 2, 2012
Rubicon Genomics chooses Velesco to manufacture its Transplex RNA Amplification kits. Velesco will manufacture the TransPlex kits for use with breast cancer diagnostics.
Feb 15, 2012
In Our Post-Pfizer Economy, Velesco is one of the companies featured in the article about companies that have sprung out of and flourished after pharmaceutical industry giant Pfizer's exit from Ann Arbor, Michigan.
April 28, 2011
Velesco expands formulation development services and clinical trial manufacturing services through collaboration with another contract research organization (CRO), Vindonwestech Storage.
Velesco Pharmaceutical Services is featured in a case study about High Purity Water for Pharmaceuticals Testing, published in the American Laboratory e-Supplement, February 2011 edition.
Velesco COO Gerry Cox describes how he went from working for drug giant Pfizer to founding Velesco Pharmaceutical Services in a Fortune Magazine article.
Velesco Pharmaceutical Services expands core scientific and quality team with the addition of a Director of Quality and Senior Pharmaceutical Scientist.
Dave Barnes, CEO of Velesco Pharmaceutical Services, is the subject of an editorial: "Stage Two Strategies" in Crain's Detroit Business.
April 14, 2010
Velesco Pharmaceutical Services receives a "Catalyst Award" for 2009 economic growth, and is recognized as a 2010 "Michigan 50 Companies to Watch" recipient.
Velesco Pharmaceutical Services joins BIOCOM, the Southern California Life Science Association.
June 9, 2009
Velesco Pharmaceutical Services opens new Clinical Trial Materials cGMP production facility where they will manufacture clinical trial supplies for pharmaceutical companies. This move provides Velesco with expanded space for analytical and drug formulation laboratory testing services. Velesco's new Laboratory Address: 46701 N. Commerce Center Drive, Suite A8, Plymouth, Michigan 48170.
April 7, 2009
Velesco's participation in the upcoming Michigan CMC Alliance featured on outsourcing-pharma.com.
February 6, 2009
Velesco Pharmaceutical Services Expands Core Scientific Team adding a Director of Analytical Chemistry and Senior Analytical Scientist.
Velesco supported the Ann Arbor Youth Chorale for their 22nd Annual Winter Concert.
November 12, 2008
Velesco Pharmaceutical Services plans to double staff in Ann Arbor.
September 23, 2008
SCORR Marketing Chosen as Agency of Record for Velesco Pharmaceutical Services.
August 15, 2008
Velesco Pharmaceutical Services has joined the Massachusetts Biotechnology Council.
July 17, 2008
Gerry Cox, Velesco's chief operating officer is profiled in the Ann Arbor Business Review.
June 2, 2008
Velesco Pharmaceutical Services has relocated into a new, purpose built laboratory testing facility in Ann Arbor, Michigan. This facility provides the necessary wet lab space with associated ancillary areas to support Velesco's near term growth plans. The laboratories were refurbished and briefly occupied by Pfizer and are state-of-the-art for pharmaceutical analytical chemistry and drug formulation science.